168 related articles for article (PubMed ID: 38496757)
1. DNA damage levels in peripheral blood mononuclear cells before and after first cycle of chemotherapy have comparable prognostic values in germ cell tumor patients.
Ivovič D; Šestáková Z; Roška J; Kálavská K; Hurbanová L; Holíčková A; Smolková B; Kabelíková P; Novotná V; Chovanec M; Palacka P; Mego M; Jurkovičová D; Chovanec M
Front Oncol; 2024; 14():1360678. PubMed ID: 38496757
[TBL] [Abstract][Full Text] [Related]
2. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer.
Sestakova Z; Kalavska K; Hurbanova L; Jurkovicova D; Gursky J; Chovanec M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Cingelova S; Spanik S; Mardiak J; Chovanec M; Mego M
Oncotarget; 2016 Nov; 7(46):75996-76005. PubMed ID: 27732956
[TBL] [Abstract][Full Text] [Related]
5. Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?
Kalavska K; Sestakova Z; Mlcakova A; Kozics K; Gronesova P; Hurbanova L; Miskovska V; Rejlekova K; Svetlovska D; Sycova-Mila Z; Obertova J; Palacka P; Mardiak J; Chovanec M; Chovanec M; Mego M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361047
[TBL] [Abstract][Full Text] [Related]
6. High Endogenous DNA Damage Levels Predict Hematological Toxicity in Testicular Germ Cell Tumor Patients Treated With First-Line Chemotherapy.
Hapakova N; Sestakova Z; Holickova A; Hurbanova L; Miskovska V; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Obertova J; Palacka P; Sycova-Mila Z; Mardiak J; Chovanec M; Mego M
Clin Genitourin Cancer; 2019 Oct; 17(5):e1020-e1025. PubMed ID: 31281064
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial.
Mego M; Rejlekova K; Svetlovska D; Miskovska V; Gillis AJM; De Angelis V; Kalavska K; Obertova J; Palacka P; Reckova M; Sycova-Mila Z; Pindak D; Chovanec M; Looijenga LHJ; Mardiak J
Eur Urol Open Sci; 2021 Nov; 33():19-27. PubMed ID: 34738090
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
9. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
[TBL] [Abstract][Full Text] [Related]
10. Development of a risk stratification system to guide treatment for female germ cell tumors.
Meisel JL; Woo KM; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Gardner GJ; Bosl GJ; Aghajanian C; Feldman DR
Gynecol Oncol; 2015 Sep; 138(3):566-72. PubMed ID: 26115974
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
[TBL] [Abstract][Full Text] [Related]
12. Placental alkaline phosphatase levels in cerebrospinal fluid can have a decisive role in the differential diagnosis of intracranial germ cell tumors.
Aihara Y; Watanabe S; Amano K; Komatsu K; Chiba K; Imanaka K; Hori T; Ohba T; Dairoku H; Okada Y; Kubo O; Kawamata T
J Neurosurg; 2018 Sep; 131(3):687-694. PubMed ID: 30265190
[TBL] [Abstract][Full Text] [Related]
13. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
Kondagunta GV; Bacik J; Bajorin D; Dobrzynski D; Sheinfeld J; Motzer RJ; Bosl GJ
J Clin Oncol; 2005 Dec; 23(36):9290-4. PubMed ID: 16361627
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
15. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Theodore C; Chevreau C; Yataqhene Y; Fizazi K; Delord JP; Lotz JP; Geoffrois L; Kerbrat P; Bui V; Flechon A
Ann Oncol; 2008 Aug; 19(8):1465-1469. PubMed ID: 18385203
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.
De Giorgi U; Rosti G; Salvioni R; Papiani G; Ballardini M; Pizzocaro G; Marangolo M
Urol Oncol; 2011; 29(3):284-90. PubMed ID: 19556152
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy for male germ cell tumor.
Hara I; Miyake H; Yamada Y; Takenaka A; Fujisawa M
Int J Urol; 2006 Aug; 13(8):1037-44. PubMed ID: 16903926
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
[TBL] [Abstract][Full Text] [Related]
19. Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors.
Honecker F; Mayer F; Stoop H; Oosterhuis JW; Koch S; Bokemeyer C; Looijenga LH
Lab Invest; 2003 Oct; 83(10):1489-95. PubMed ID: 14563950
[TBL] [Abstract][Full Text] [Related]
20. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
